Lexaria Bioscience Corp. (NASDAQ:LEXX) Shares Bought by XTX Topco Ltd

XTX Topco Ltd increased its position in Lexaria Bioscience Corp. (NASDAQ:LEXX) by 47.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,626 shares of the company’s stock after acquiring an additional 6,024 shares during the period. XTX Topco Ltd owned approximately 0.12% of Lexaria Bioscience worth $57,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Armistice Capital LLC acquired a new position in Lexaria Bioscience during the 2nd quarter worth $2,836,000. Renaissance Technologies LLC bought a new stake in shares of Lexaria Bioscience during the second quarter valued at about $63,000. Finally, HighTower Advisors LLC bought a new stake in Lexaria Bioscience during the third quarter worth approximately $40,000. Institutional investors and hedge funds own 13.06% of the company’s stock.

Lexaria Bioscience Price Performance

Shares of LEXX opened at $2.23 on Monday. Lexaria Bioscience Corp. has a 12-month low of $1.20 and a 12-month high of $6.85. The stock has a market capitalization of $38.92 million, a P/E ratio of -4.74 and a beta of 0.99. The firm’s 50 day moving average is $2.36 and its 200-day moving average is $2.87.

Insider Transactions at Lexaria Bioscience

In related news, CEO Richard Christopher purchased 22,828 shares of Lexaria Bioscience stock in a transaction dated Monday, December 2nd. The stock was acquired at an average cost of $2.24 per share, with a total value of $51,134.72. Following the completion of the transaction, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at $51,134.72. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 26.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Lexaria Bioscience in a research note on Monday, December 2nd.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.